Business Description
Conmed Corp
NAICS : 334510
SIC : 3845
ISIN : US2074101013
Share Class Description:
FRA:EC8: Ordinary SharesDescription
Conmed Corp is a Utica, New York-based medical equipment company that focuses on sports medicine procedures and general surgeries. The firm currently reports through two reporting units, orthopedic surgery, and general surgery. From a geographic perspective, the firm is U.S.-centric, with maximum domestic sales accounting for revenue, EMEA accounting for second place, APAC at third, and the non-U.S. Americas region driving the remaining revenue.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.4 | |||||
| Debt-to-Equity | 1.01 | |||||
| Debt-to-EBITDA | 3.49 | |||||
| Interest Coverage | 5.22 | |||||
| Piotroski F-Score | 9/9 | |||||
| Altman Z-Score | 2.29 | |||||
| Beneish M-Score | -2.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.5 | |||||
| 3-Year EBITDA Growth Rate | 15 | |||||
| 3-Year EPS without NRI Growth Rate | 120.9 | |||||
| 3-Year FCF Growth Rate | 24.4 | |||||
| 3-Year Book Growth Rate | 3.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 18.26 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.53 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 88.18 | |||||
| 9-Day RSI | 73.76 | |||||
| 14-Day RSI | 63.98 | |||||
| 6-1 Month Momentum % | -6.15 | |||||
| 12-1 Month Momentum % | -35.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.27 | |||||
| Quick Ratio | 1.06 | |||||
| Cash Ratio | 0.14 | |||||
| Days Inventory | 208.47 | |||||
| Days Sales Outstanding | 67.12 | |||||
| Days Payable | 61.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.14 | |||||
| Dividend Payout Ratio | 0.21 | |||||
| Forward Dividend Yield % | 1.12 | |||||
| 5-Year Yield-on-Cost % | 1.14 | |||||
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | 4.62 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.65 | |||||
| Operating Margin % | 15.37 | |||||
| Net Margin % | 10.23 | |||||
| FCF Margin % | 12.88 | |||||
| ROE % | 15.32 | |||||
| ROA % | 5.71 | |||||
| ROIC % | 7.47 | |||||
| 3-Year ROIIC % | -34.27 | |||||
| ROC (Joel Greenblatt) % | 46.57 | |||||
| ROCE % | 9.89 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 16.74 | |||||
| Forward PE Ratio | 14.33 | |||||
| PE Ratio without NRI | 18.16 | |||||
| Shiller PE Ratio | 54.35 | |||||
| Price-to-Owner-Earnings | 11.66 | |||||
| PS Ratio | 1.71 | |||||
| PB Ratio | 2.33 | |||||
| Price-to-Free-Cash-Flow | 13.26 | |||||
| Price-to-Operating-Cash-Flow | 12.24 | |||||
| EV-to-EBIT | 16.1 | |||||
| EV-to-Forward-EBIT | 24.24 | |||||
| EV-to-EBITDA | 11.81 | |||||
| EV-to-Forward-EBITDA | 16.5 | |||||
| EV-to-Revenue | 2.47 | |||||
| EV-to-Forward-Revenue | 3.66 | |||||
| EV-to-FCF | 18.54 | |||||
| Price-to-Projected-FCF | 1.46 | |||||
| Price-to-Median-PS-Value | 0.71 | |||||
| Earnings Yield (Greenblatt) % | 6.21 | |||||
| FCF Yield % | 7.27 | |||||
| Forward Rate of Return (Yacktman) % | 2.93 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Conmed Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1,181.057 | ||
| EPS (TTM) (€) | 3.85 | ||
| Beta | 0.78 | ||
| Volatility % | 33.24 | ||
| 14-Day RSI | 63.98 | ||
| 14-Day ATR (€) | 1.059367 | ||
| 20-Day SMA (€) | 58.975 | ||
| 12-1 Month Momentum % | -35.11 | ||
| 52-Week Range (€) | 56 - 104 | ||
| Shares Outstanding (Mil) | 30.89 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Conmed Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Conmed Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Conmed Corp Frequently Asked Questions
What is Conmed Corp(FRA:EC8)'s stock price today?
The current price of FRA:EC8 is €64.50. The 52 week high of FRA:EC8 is €104.00 and 52 week low is €56.00.
When is next earnings date of Conmed Corp(FRA:EC8)?
The next earnings date of Conmed Corp(FRA:EC8) is 2025-01-31 Est..
Does Conmed Corp(FRA:EC8) pay dividends? If so, how much?
The Dividend Yield %  of Conmed Corp(FRA:EC8) is 1.14% (As of Today), Highest Dividend Payout Ratio of Conmed Corp(FRA:EC8) was 2.5. The lowest was 0.21. And the median was 0.69. The  Forward Dividend Yield % of Conmed Corp(FRA:EC8) is 1.12%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers